Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study
Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)
DOI: 10.6004/jnccn.2026.7058 ↗Abstract
Background: Metastatic sarcomatoid renal cell carcinoma (msRCC) is an aggressive disease typically associated with poor outcomes following VEGF-targeted therapies. This study evaluated in real-world outcomes in patients with msRCC based on whether they received treatment with immune checkpoint inhibitors (ICIs). Methods: We conducted a multi-institutional, retrospective study of patients who received systemic therapy for msRCC between July 2010 and June 2020. In total, 203 patients across 6 US academic centers were included. Patients were categorized into 2 groups based on whether they received ICIs: ICI+ (n=155) and ICI− (n=48). Overall survival (OS) was estimated using the Kaplan–Meier method and measured from the initiation of frontline systemic therapy. Treatment responses were evaluated by investigators at participating centers. Results: After a median follow-up of 48.1 months, OS was significantly longer in the ICI+ group (median OS, 31.0 vs 7.6 months; hazard ratio [HR], 0.38; 95% CI, 0.26–0.56; P
EUVIMED